Xcout Intel
Aurin Biotech Inc.
Aurion Biotech Inc. develops regenerative cell therapies for ophthalmology, focusing on treatments for corneal endothelial disease and vision loss. Its lead product, AURN001, is a combination therapy utilizing human corneal endothelial cells designed to restore corneal clarity and provide a minimally invasive alternative to traditional donor tissue transplantation. The company serves patients suffering from blindness and provides advanced treatment options for ophthalmologists.
Subscribe to see Aurin Biotech Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Aurin Biotech Inc. at a glance
Aurin Biotech Inc. is a biotechnology company headquartered in Canada. Its most recent funding round raised $795,029 in May 2018. Xcout tracks 33 named people at Aurin Biotech Inc., including Jeannette Bankes (President CEO of GE HealthCare’s Patient Care Solutions segment).
Aurin Biotech Inc. leadership
- Jeannette BankesPresident CEO of GE HealthCare’s Patient Care Solutions segment
- Andrew Torres, PhDChief Manufacturing Officer
- Edward J. Holland, MDChief Medical Officer
- Sterling ChungChief Regulatory & Quality Officer
- ARNAUD LACOSTECEO and Chief Scientific Officer
- Eris P. JordanChief Development Officer
27 more named people on record for Aurin Biotech Inc., with roles, board committees and tenure — see the full roster →
Aurin Biotech Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $795,029 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Aurin Biotech Inc. competitors
A few of Aurin Biotech Inc.'s closest competitors — see the full list of competitors and alternatives →
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company works to deliver advanced retinal gene therapies to patients experiencing blindness.
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing treatments that preserve the sight of individuals impacted by severe eye diseases.
Atsena Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Durham, North Carolina, established in 2019. The firm focuses on developing novel gene therapies to treat debilitating inherited blinding diseases using proprietary vector delivery technologies. Its scientific pipeline aims to address areas of high unmet medical need in ophthalmology.
Autonomy Bio Inc. is a biotechnology company focused on developing human aging therapeutics aimed at extending healthspan and mitigating age-related decline. The company targets individuals seeking to maintain health and independence as they age.
Clearside Biomedical, Inc. operates as a biopharmaceutical company, specializing in novel approaches to administer therapies to the posterior region of the eye via the suprachoroidal space. Its market-approved product, XIPERE, is an injectable suspension containing triamcinolone acetonide, utilized to manage macular edema associated with uveitis. Additionally, the firm is progressing CLS-AX, an axitinib injectable suspension intended for suprachoroidal injection, having concluded its Phase 2 clinical trial for the treatment of wet age-related macular degeneration (AMD). Strategic collaborations are in place with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Founded in 2011 and headquartered in Alpharetta, Georgia, Clearside Biomedical regrettably initiated Chapter 11 reorganization proceedings by filing a voluntary petition with the U.S. Bankruptcy Court for the District of Delaware on November 23, 2025.
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Get Aurin Biotech Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Aurin Biotech Inc. in Xcout Intel
- 33 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access